Today's Date: March 29, 2024
Five UBS Financial Advisors in Southern California and Hawaii named Top Women Wealth Advisors by Forbes   •   University of Phoenix College of Doctoral Studies Highlights Scholarship Published by Working Adult Students and Graduates   •   BiaTech Joins NVIDIA Inception   •   World Class Dyslexia, Literacy, and Neuroscience Experts Gather with Educators for Two-Day Professional Learning Event   •   Syngenta Group reports $32.2 billion sales and $4.6 billion EBITDA in 2023   •   Segal Unveils 2024 State Employee Health Benefit Study and Interactive Plan Comparison Map Tool   •   Navigating Birth Control: Expert Advice from Dr. Bana Kashani, OB-GYN   •   Charity Navigator Launches Women's Advocacy List for Women's History Month   •   101 Mobility® Eden Prairie: Leading the Way in Mobility and Accessibility Solutions   •   Matters of State Strategies Names Matt Capalby As VP of Government Affairs   •   e.l.f. Cosmetics Debuts TikTok Shop Super Brand Day   •   Navigating Spring Break Sexual Health: Advice from Dr. Deb Laino Sex and Relationship Therapist and Powerful Life Coach   •   Walmart Connect Announced as Presenting Sponsor of the 2024 WIN Summit   •   Unique online yoga platform offers lifeline for menopausal women   •   Nicklaus Children's Hospital Achieves Fifth Consecutive Magnet® Recognition   •   Naropa University Launches Pioneering Psychedelic Minor     •   AMIGOS FOR KIDS LAUNCHES "THE MISSING REVIEW"   •   Seniors Helping Seniors® In-Home Care Services Expands to North Houston   •   Committee for Children Now Offers a PreK-12 Full-Suite Solution with the Highly Anticipated Launch of Second Step® High Scho   •   Ministry of Tourism of the Dominican Republic Comes Back to Miami with Its Second Edition Tradeshow
Bookmark and Share

LUCA Science Announces Joint Research with the University of Oxford, Nuffield Department of Women's & Reproductive Health, o

TOKYO , September 29 /Businesswire/ - LUCA Science (Tokyo, Japan), a biotechnology company pioneering a novel class of mitochondrial therapeutics, announced today that it will collaborate with the University of Oxford’s Nuffield Department of Women's & Reproductive Health, in joint research utilising LUCA Science’s proprietary drug delivery platform technology for the treatment of IUGR.

This collaboration was instigated by Dr Yosuke Matsumiya, the UK project director for LUCA Science, who will be coordinating the research with the University of Oxford.

About the Joint Research

The placenta is a unique organ across which nutrients are transferred from mother to baby. Abnormal placental function causes significant problems in pregnancy, including IUGR.

IUGR affects over 10 million babies worldwide/year with 200,000 deaths related to IUGR and survivors (often delivered prematurely) face not only the sequelae of preterm birth but also increased long-term risks of disease (metabolic & cardiac). The largest global causes of IUGR are malnutrition and/or failure of the placenta to effectively transfer nutrition to the baby.

Currently the only treatment for IUGR is delivery irrespective of gestation. Increasing placental cellular bioenergetics and maintaining its function is a logical alternative solution. This collaboration was formed in order to realise this solution and seeks to address this by specifically delivering therapeutics to the placenta, combining unique technology developed at LUCA Science in Japan with extensive placental research experience at the University of Oxford.

Comment from Dr. Manu Vatish*1 at the University of Oxford.

“We are very excited to be working with LUCA Science to address one of the major obstacles in obstetric care. LUCA Science’s cutting-edge technology provides a unique solution to this intractable clinical problem. Use of their novel solution to deliver mitochondria to placental tissues would increase local energy supply to a starving fetus and be a major step in developing treatments for a condition affecting vast numbers of babies worldwide.”

About LUCA Science

LUCA Science is a preclinical stage biopharmaceutical company pioneering a new class of mitochondrial therapy to restore cellular bioenergetics in dysfunctional or damaged tissues and organs. Mitochondria are the power plants in our cells that produce energy for our bodies. LUCA Science has developed a novel method to isolate proprietary functional mitochondria which can then be stored and delivered as a biopharmaceutical agent. The advanced delivery system can be applied not just for mitochondria but also other compounds that can improve bioenergetics in specific cells or tissues.

LUCA Science recently completed $9.8 million Series A financing in September.

*1: Senior Clinical Fellow at the Nuffield Department of Women's and Reproductive Health.

LUCA Science Inc.

Name

:

LUCA Science Inc.

Headquarters

:

3-8-3, Nihonbashi Honcho, Chuo-ku, Tokyo, 103-0023, Japan

CEO

:

Rick C. Tsai DMD, MD

Established

:

December 25th 2018

Employees

:

12

URL

:

https://luca-science.com

Business

:

Research and development of mitochondrial biopharmaceuticals

 


STORY TAGS: Europe, Japan, United Kingdom, Asia Pacific, Research, Women, Baby/Maternity, Biotechnology, University, Pharmaceutical, Consumer, Health, Science, Education, Contract/Agreement,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News